Recognition and Maturation of IL-18 by Caspase-4 Noncanonical Inflammasome
Affiliations
The canonical (caspase-1) and noncanonical (comprising caspases 4, 5 and 11; hereafter, caspase-4/5/11) inflammasomes both cleave gasdermin D (GSDMD) to induce pyroptosis. Whereas caspase-1 processes IL-1β and IL-18 for maturation, no cytokine target has been firmly established for lipopolysaccharide-activated caspase-4/5/11. Here we show that activated human caspase-4, but not mouse caspase-11, directly and efficiently processes IL-18 in vitro and during bacterial infections. Caspase-4 cleaves the same tetrapeptide site in pro-IL-18 as caspase-1. The crystal structure of the caspase-4-pro-IL-18 complex reveals a two-site (binary) substrate-recognition mechanism; the catalytic pocket engages the tetrapeptide, and a unique exosite that critically recognizes GSDMD similarly binds to a specific structure formed jointly by the propeptide and post-cleavage-site sequences in pro-IL-18. This binary recognition is also used by caspase-5 as well as caspase-1 to process pro-IL-18. In caspase-11, a structural deviation around the exosite underlies its inability to target pro-IL-18, which is restored by rationally designed mutations. The structure of pro-IL-18 features autoinhibitory interactions between the propeptide and the post-cleavage-site region, preventing recognition by the IL-18Rα receptor. Cleavage by caspase-1, -4 or -5 induces substantial conformational changes of IL-18 to generate two critical receptor-binding sites. Our study establishes IL-18 as a target of lipopolysaccharide-activated caspase-4/5. The finding is paradigm shifting in the understanding of noncanonical-inflammasome-mediated defences and also the function of IL-18 in immunity and disease.
New insights into the noncanonical inflammasome point to caspase-4 as a druggable target.
Elkayam E, Gervais F, Wu H, A Crackower M, Lieberman J Nat Rev Immunol. 2025; .
PMID: 40044809 DOI: 10.1038/s41577-025-01142-9.
Development of anti-murine IL-18 binding protein antibodies to stimulate IL-18 bioactivity.
Huard A, Fauteux-Daniel S, Goldstein J, Martin P, Jarlborg M, Andries J J Immunol. 2025; 214(1):180-191.
PMID: 40018678 PMC: 7617445. DOI: 10.1093/jimmun/vkae022.
Qian Y, Liu Q, Cheng X, Wang C, Kong C, Li M Elife. 2025; 13.
PMID: 39998486 PMC: 11856931. DOI: 10.7554/eLife.99939.
Short IL-18 generated by caspase-3 cleavage mobilizes NK cells to suppress tumor growth.
Shen J, Zhang Y, Tang W, Yang M, Cheng T, Chen Y Nat Immunol. 2025; 26(3):416-428.
PMID: 39891018 DOI: 10.1038/s41590-024-02074-7.
Zhou J, Liu C, Wang X, Liu Z, Ming Z, Wang Y PLoS Pathog. 2025; 21(1):e1012877.
PMID: 39854601 PMC: 11760013. DOI: 10.1371/journal.ppat.1012877.